Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

BIIE-0246

Inquiry
Cat. No.: OB0425LY-011
Synonyms: 246146-55-4; BIIE 0246; BIIE0246; Ar-H-053591; (2S)-5-(Diaminomethylideneamino)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-2-[[2-[1-[2-oxo-2-[4-(6-oxo-5,11-dihydrobenzo[c][1]benzazepin-11-yl)piperazin-1-yl]ethyl]cyclopentyl]acetyl]amino]pentanamide; N-[(1S)-4-[(Amino-iminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-cyclopentaneacetamide
Size: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg
CAS No.: 246146-55-4
Compound CID: 9811493
BIIE-0246

Specification

Description: BIIE-0246 is a selective NPY2R antagonist that decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated.
Formula Weight: 896.05
Applications: BIIE-0246 has been extensively studied for use in models of cardiovascular and obesity diseases.
Storage: Storage at -20°C.
Formula: C49H57N11O6
Appearance: Solid
Purity: 0.991
Pathway: GPCR/G protein; Neuronal signaling
Identity: Confirmed by NMR.
Target: Neuropeptide Y receptor

Library Information

Inquiry

Copyright © Protheragen. All rights reserves.